Literature DB >> 11586361

An endogenous cannabinoid (2-AG) is neuroprotective after brain injury.

D Panikashvili1, C Simeonidou, S Ben-Shabat, L Hanus, A Breuer, R Mechoulam, E Shohami.   

Abstract

Traumatic brain injury triggers the accumulation of harmful mediators that may lead to secondary damage. Protective mechanisms to attenuate damage are also set in motion. 2-Arachidonoyl glycerol (2-AG) is an endogenous cannabinoid, identified both in the periphery and in the brain, but its physiological roles have been only partially clarified. Here we show that, after injury to the mouse brain, 2-AG may have a neuroprotective role in which the cannabinoid system is involved. After closed head injury (CHI) in mice, the level of endogenous 2-AG was significantly elevated. We administered synthetic 2-AG to mice after CHI and found significant reduction of brain oedema, better clinical recovery, reduced infarct volume and reduced hippocampal cell death compared with controls. When 2-AG was administered together with additional inactive 2-acyl-glycerols that are normally present in the brain, functional recovery was significantly enhanced. The beneficial effect of 2-AG was dose-dependently attenuated by SR-141761A, an antagonist of the CB1 cannabinoid receptor.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11586361     DOI: 10.1038/35097089

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  197 in total

1.  Israel: Research without prejudice.

Authors:  Emily Sohn
Journal:  Nature       Date:  2015-09-24       Impact factor: 49.962

Review 2.  Endocannabinoids in cerebrovascular regulation.

Authors:  Zoltán Benyó; Éva Ruisanchez; Miriam Leszl-Ishiguro; Péter Sándor; Pál Pacher
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-01-29       Impact factor: 4.733

3.  Palmitoyl Serine: An Endogenous Neuroprotective Endocannabinoid-Like Entity After Traumatic Brain Injury.

Authors:  Aniv Mann; Reem Smoum; Victoria Trembovler; Alexander Alexandrovich; Aviva Breuer; Raphael Mechoulam; Esther Shohami
Journal:  J Neuroimmune Pharmacol       Date:  2015-02-27       Impact factor: 4.147

4.  Endocannabinoid metabolism in neurodegenerative diseases.

Authors:  Chu Chen
Journal:  Neuroimmunol Neuroinflamm       Date:  2016-12-15

Review 5.  Antiinflammatory and neuroprotective actions of COX2 inhibitors in the injured brain.

Authors:  Kenneth I Strauss
Journal:  Brain Behav Immun       Date:  2007-11-08       Impact factor: 7.217

6.  Detection of Cyclooxygenase-2-Derived Oxygenation Products of the Endogenous Cannabinoid 2-Arachidonoylglycerol in Mouse Brain.

Authors:  Amanda J Morgan; Philip J Kingsley; Michelle M Mitchener; Megan Altemus; Toni A Patrick; Andrew D Gaulden; Lawrence J Marnett; Sachin Patel
Journal:  ACS Chem Neurosci       Date:  2018-05-09       Impact factor: 4.418

Review 7.  [Therapeutic use of cannabinoids in neurology].

Authors:  P Schwenkreis; M Tegenthoff
Journal:  Schmerz       Date:  2003-10       Impact factor: 1.107

8.  Inhibition of monoacylglycerol lipase prevents chronic traumatic encephalopathy-like neuropathology in a mouse model of repetitive mild closed head injury.

Authors:  Jian Zhang; Zhaoqian Teng; Yunping Song; Mei Hu; Chu Chen
Journal:  J Cereb Blood Flow Metab       Date:  2014-12-10       Impact factor: 6.200

Review 9.  Biosynthesis of endocannabinoids and their modes of action in neurodegenerative diseases.

Authors:  Mario van der Stelt; Henrik H Hansen; Wouter B Veldhuis; Peter R Bär; Klaas Nicolay; Gerrit A Veldink; Johannes F G Vliegenthart; Harald S Hansen
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

10.  Role of CB2 Receptor in the Recovery of Mice after Traumatic Brain Injury.

Authors:  Lital Magid; Sami Heymann; Merav Elgali; Liat Avram; Yoram Cohen; Sigal Liraz-Zaltsman; Raphael Mechoulam; Esther Shohami
Journal:  J Neurotrauma       Date:  2019-02-07       Impact factor: 5.269

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.